6 research outputs found
āļāļēāļĢāđāļāļĢāļĩāļĒāļĄāđāļāļĢāļēāļāļīāļāļēāđāļĄāļāđāđāļĨāļ°āļĨāļĩāđāļ§āļāļĨāļāļāļāļēāļāļīāļāđāļāļĢāļĨāļīāđāļāđāļāļĄ āđāļĨāļ°āļāļ§āļēāļĄāđāļāđāļāđāļāđāļāđāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāļ§āļąāļāđāļĢāļāļāļāļ
Thesis (Ph.D., Pharmaceutical Sciences)--Prince of Songkla University, 201
āļāļēāļĢāļāļąāļāļāļēāļāļģāļĢāļąāļ Bacillus megaterium āđāļāļĢāļđāļāđāļāļāđāļāļĢāļāļāļđāļĨāđāļĨāļ°āđāļĄāđāļāđāļāļ·āđāļāļāļ§āļāļāļļāļĄāđāļĢāļāļāļēāļāđāļāđāļŦāđāļāļāļāļāļāđāļēāļ§
Thesis (M.Pharm., Pharmaceutical Sciences)--Prince of Songkla University, 200
Isoniazid Proliposome Powders for InhalationâPreparation, Characterization and Cell Culture Studies
The aims of this study were to develop proliposome powders containing isoniazid (INH) in a dry powder aerosol form. INH-proliposome powders were prepared by a spray drying method. Proliposome physicochemical properties were determined using cascade impactor, X-ray diffraction and differential scanning calorimetry. The toxicity of proliposomes to respiratory-associated cell lines and its potential to provoke immunological responses from alveolar macrophages (AM) were determined. Free INH and INH-proliposome bioactivities were tested in vitro and in AM infected with Mycobacterium bovis (M. bovis). Aerosolization properties of INH-proliposome powders at 60 L/min, the powders showed mass median aerodynamic diameters of 2.99â4.92 mm, with fine particle fractions (aerosolized particles less than 4.4 Âĩm) of 15â35%. Encapsulation of INH was 18â30%. Proliposome formulations containing INH to mannitol ratios of 4:6 and 6:4 exhibited the greatest overlapping peak between the drug and mannitol. INH-proliposomes were evidently nontoxic to respiratory-associated cells, and did not activate AM to produce inflammatory mediatorsâincluding interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a), and nitric oxideâat a toxic level. The efficacy of INH-proliposome against AM infected with M. bovis was significantly higher than that of free INH (p < 0.05). INH-proliposomes are potential candidates for an alternative tuberculosis treatment
Isoniazid Proliposome Powders for InhalationâPreparation, Characterization and Cell Culture Studies
Abstract: The aims of this study were to develop proliposome powders containing isoniazid (INH) in a dry powder aerosol form. INH-proliposome powders were prepared by a spray drying method. Proliposome physicochemical properties were determined using cascade impactor, X-ray diffraction and differential scanning calorimetry. The toxicity of proliposomes to respiratory-associated cell lines and its potential to provoke immunological responses from alveolar macrophages (AM) were determined. Free INH and INH-proliposome bioactivities were tested in vitro and in AM infected with Mycobacterium bovis (M. bovis). Aerosolization properties of INH-proliposome powders at 60 L/min, the powders showed mass median aerodynamic diameters of 2.99â4.92 ïŋ―m, with fine particle fractions (aerosolized particles less than 4.4 Âĩm) of 15â35%. Encapsulation of INH was 18â30%. Proliposome formulations containing INH to mannitol ratios of 4:6 and 6:4 exhibited the greatest overlapping peak between the drug and mannitol. INH-proliposomes were evidently nontoxic to respiratory-associated cells, and did not activate AM to produce inflammatory mediatorsâincluding interleukin-1 ïŋ― (IL-1ïŋ―), tumor necrosis factor-ïŋ― (TNF-ïŋ―), and nitric oxideâat a toxic level. The efficacy of INH-proliposome against A
Levofloxacin-Proliposomes: Opportunities for Use in Lung Tuberculosis
Levofloxacin (LEV) is a relatively new-generation fluoroquinolone antibiotic that has good activity against <em>Mycobacterium tuberculosis</em>. The aims of this study were to develop and evaluate LEV-proliposomes in a dry powder aerosol form for pulmonary delivery. LEV-proliposomes containing LEV, soybean phosphatidylcholine, cholesterol and porous mannitol were prepared by a spray drying technique. The physicochemical properties of LEV-proliposomes were determined using a cascade impactor, X-ray diffraction (XRD), differential scanning calorimetry (DSC) and Fourier transform <em><em>infrared</em></em><em> </em>spectroscopy (FT-IR). The toxicity of proliposomes to respiratory-associated cell lines and its potential to provoke immunological responses from alveolar macrophages (AMs) were evaluated. Antimycobacterial activity using flow cytometry and an <em>in vivo</em> repeated dose toxicity test in rats were carried out. LEV-proliposomes were successfully prepared with mass median aerodynamic diameters of 4.15â4.44 Ξm and with fine particle fractions (aerosolized particles of less than 4.4 Âĩm) of 13%â38% at 60 L/min. LEV-proliposomes were less toxic to respiratory-associated cells than LEV, and did not activate AMs to produce inflammatory mediators that included interleukin-1Îē (IL-1Îē), tumor necrosis factor-Îą (TNF-Îą), and nitric oxide. The minimum inhibitory concentration (MIC) against <em>M. bovis</em> of LEV and LEV-proliposomes containing LEV 10% were 1 and 0.5 Âĩg/mL, respectively. The efficacy of LEV-proliposomes against <em>M. bovis</em> was significantly higher than that of free LEV (<em>p</em> < 0.05). The efficacy of the LEV-proliposomes against <em>M. tuberculosis</em> was equal to that of the free LEV (MIC = 0.195 Âĩg/mL). In a repeated dose toxicity study in rats, renal and liver toxicity was not observed. LEV-proliposomes should now be tested as an alternative formulation for delivering LEV to the lower airways